Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.179
Sell
RSI(14)
41.096
Neutral
STOCH(KDJ)(9,3,3)
26.828
Buy
ATR(14)
0.375
High Vlolatility
CCI(14)
-95.450
Neutral
Williams %R
71.429
Sell
TRIX(12,20)
-0.433
Sell
StochRSI(14)
100.000
Buy
Search
CorMedix Inc
CRMDAdd to Watchlist
7.530USD
+0.040+0.53%
Close 07-31 16:00（ET）Quotes delayed by 15 min
590.74MMarket Cap
3.10P/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+0.53%
5 Days
-4.32%
1 Month
-13.94%
6 Months
-7.83%
Year to Date
-35.25%
1 Year
-35.31%
Key Figures
7.490Open
7.550High
637.87KVolume
3.10P/E TTM
42.81P/E Dynamic
--Dividend TTM
0.81%Turnover Ratio
7.490Prev. Close
7.300Low
3.75MTurnover
LossP/E Static
1.35P/B
0.00%Div Yield TTM
37.51%ROA
17.43052wk High
0.57Volume Ratio
-17.93MNet Profit
78.40MShares
2.4327EPS TTM
1.46Beta
65.59%ROE
6.12552wk Low
3.34%Amplitude
82.50%Gross Margin
590.74MMarket Cap
-4.67Reward/Risk
3.17%Risk Rate
TradingKey Stock Score of CorMedix Inc
Currency: USD Updated: 2026-07-31Key Insights
CorMedix Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 40 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 15.20.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
CorMedix Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
CorMedix Inc Highlights
StrengthsRisks
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is 3.10, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 43.28M shares, decreasing 30.09% quarter-over-quarter.
Held by Chuck Royce
Star Investor Chuck Royce holds 1.52M shares of this stock.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
15.200
Target Price
+101.86%
Upside Space
CorMedix Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
5
analysts
Buy
Current Rating
15.200
Target Price
+101.86%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
CorMedix Inc
CRMD
5
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
32
Pfizer Inc
PFE
32
1
2
3
...
32
Indicators
Moving Average
Indicators
Value
Direction
MA5
7.432
Buy
MA10
7.699
Sell
MA20
8.113
Sell
MA50
8.278
Sell
MA100
7.737
Sell
MA200
8.640
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
CorMedix Inc Info
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
Ticker SymbolCRMD
CompanyCorMedix Inc
CEOTodisco (Joseph)
Websitehttps://cormedix.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-2.51%
+0.32%
-1.45%
-0.92%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
-0.90%
+1.30%
-2.15%Popular Instruments
52909.700
+531.700 (+1.01%)
28414.600
+253.700 (+0.90%)
7534.600
+59.500 (+0.80%)
14613.000
-136.000 (-0.92%)
62978.000
+126.000 (+0.20%)
6421.200
+55.800 (+0.88%)
78.650
-7.284 (-8.48%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4048.120
+6.690 (+0.17%)
FAQs
What is the current price of CorMedix Inc (CRMD)?
The current price of CorMedix Inc (CRMD) is 7.53.
What is the symbol of CorMedix Inc?
The ticker symbol of CorMedix Inc is CRMD.
What is the 52-week high of CorMedix Inc?
The 52-week high of CorMedix Inc is 17.43.
What is the 52-week low of CorMedix Inc?
The 52-week low of CorMedix Inc is 6.12.
What is the market capitalization of CorMedix Inc?
The market capitalization of CorMedix Inc is 590.74M.
Is CorMedix Inc (CRMD) currently rated as Buy, Hold, or Sell?
According to analysts, CorMedix Inc (CRMD) has an overall rating of Buy, with a price target of 15.20.
What is the Earnings Per Share (EPS TTM) of CorMedix Inc (CRMD)?
The Earnings Per Share (EPS TTM) of CorMedix Inc (CRMD) is 2.26.